Introduction
HAE, Glioblastoma, hematologic adverse
GLIOBLASTOMA, PRIMARY BRAIN TUMOR
Glioblastoma is the most common malignant primary brain tumor in adults and has a detrimental prognosis despite standard-of-care treatment with surgery, radiotherapy, and temozolomide chemotherapy [The aim of the present study is to provide a detailed analysis of patterns, predictors and prognostic effect of high grade hematologic adverse event (HAE) in the CeTeG/NOA-09 trial.